BioSpace News Archive

Tharimmune, Inc. announced the closing of its previously announced public offering of an aggregate of 11,000,000 shares of its common stock in lieu thereof), including the partial exercise of the underwriter’s over-allotment option.

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced it will host a virtual KOL Event on December 4, 2023 at 12:00 PM ET to discuss the positive topline results recently announced from Part 2 of Phase 1b/2a trial of BX004 in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) infections.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative colitis.

Nevro Corp. (NYSE: NVRO) today announced that it has acquired Vyrsa Technologies (“Vyrsa”), a privately held medical technology company focused on a minimally invasive treatment option for patients suffering from chronic sacroiliac joint (“SI Joint”) pain.

Cyclerion Therapeutics, Inc., a biopharmaceutical company on a mission to develop treatments for serious diseases, announced the appointments of Dina Katabi, Ph.D., and Michael Higgins to its Board of Directors.

Cerecin Inc., a clinical-stage biotechnology company at the forefront of developing innovative neurotherapeutics, is pleased to announce the establishment of a Memorandum of Understanding with A*STAR’s Institute of Molecular and Cell Biology.

TransCode Therapeutics, Inc. announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 5,000,000 shares of common stock at a purchase price of $0.242 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules.

CooperCompanies announced that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023.

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, will present new data and study results across its Precision Oncology and hereditary cancer platforms at the 2023 annual San Antonio Breast Cancer Symposium.

AMN Healthcare (NYSE: AMN), the leader and innovator in total talent solutions for healthcare organizations across the United States, today announced it has closed on the acquisition of MSDR.